TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 0.300nMAssay Description:The activity of EZH2 enzyme (with A677G mutant or Y641F mutant) was tested by the following method.The method was used to determine the inhibitory ef...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 0.300nMAssay Description:The activity of EZH2 enzyme (with A677G mutant or Y641F mutant) was tested by the following method.The method was used to determine the inhibitory ef...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 0.520nMAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 0.520nMAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 0.520nMT: 2°CAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 0.760nMAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 0.760nMAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 0.760nMT: 2°CAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 0.800nMAssay Description:The activity of EZH2 enzyme (with A677G mutant or Y641F mutant) was tested by the following method.The method was used to determine the inhibitory ef...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 0.800nMAssay Description:The activity of EZH2 enzyme (with A677G mutant or Y641F mutant) was tested by the following method.The method was used to determine the inhibitory ef...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 0.870nMAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 0.870nMT: 2°CAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 0.870nMAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 1nMAssay Description:The assays were performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG, 100 mM KCl and 0.002% Tween20, prepared on the day...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 1.12nMAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 1.12nMT: 2°CAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 1.12nMAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 1.40nMAssay Description:Test compounds were serially diluted 3-fold in DMSO in a 10 point-curve and 1 uL was spotted into a 384-well microplate in duplicate using a Platemat...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 1.5nMAssay Description:Test compounds were serially diluted 3-fold in DMSO in a 10 point-curve and 1 uL was spotted into a 384-well microplate in duplicate using a Platemat...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 1.5nMAssay Description:Test compounds were serially diluted 3-fold in DMSO in a 10 point-curve and 1 uL was spotted into a 384-well microplate in duplicate using a Platemat...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 1.55nMAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 1.55nMAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 1.55nMT: 2°CAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 1.60nMAssay Description:Test compounds were serially diluted 3-fold in DMSO in a 10 point-curve and 1 uL was spotted into a 384-well microplate in duplicate using a Platemat...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 1.63nMT: 2°CAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 1.63nMAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 1.63nMAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 1.82nMAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 1.82nMAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 1.82nMT: 2°CAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 1.95nMAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 1.95nMAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 1.95nMT: 2°CAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 2.07nMT: 2°CAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 2.07nMAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 2.07nMAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 2.19nMAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 2.19nMT: 2°CAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 2.19nMAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 2.23nMAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 2.23nMAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 2.23nMT: 2°CAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 2.30nMAssay Description:The activity of EZH2 enzyme (with A677G mutant or Y641F mutant) was tested by the following method.The method was used to determine the inhibitory ef...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 2.30nMAssay Description:The activity of EZH2 enzyme (with A677G mutant or Y641F mutant) was tested by the following method.The method was used to determine the inhibitory ef...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 2.5nMAssay Description:Test compounds were serially diluted 3-fold in DMSO in a 10 point-curve and 1 uL was spotted into a 384-well microplate in duplicate using a Platemat...More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 2.56nMT: 2°CAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 2.56nMAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 2.56nMAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 2.60nMAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair
TargetHistone-lysine N-methyltransferase EZH2 [Y641F](Homo sapiens (Human))
Jiangsu Hengrui Medicine
US Patent
Jiangsu Hengrui Medicine
US Patent
Affinity DataIC50: 2.60nMT: 2°CAssay Description:The assays were all performed in a buffer consisting of 20 mM bicine (pH=7.6), 0.5 mM DTT, 0.005% BSG and 0.002% Tween20, prepared on the day of use....More data for this Ligand-Target Pair